Literature DB >> 8174969

Intestinal bile acid malabsorption in cystic fibrosis.

S O'Brien1, H Mulcahy, H Fenlon, A O'Broin, M Casey, A Burke, M X FitzGerald, J E Hegarty.   

Abstract

This study aimed at examining the mechanisms participating in excessive faecal bile acid loss in cystic fibrosis. The study was designed to define the relation between faecal fat and faecal bile acid loss in patients with and without cystic fibrosis related liver disease; to assess terminal ileal bile acid absorption by a seven day whole body retention of selenium labelled homotaurocholic acid (SeHCAT); and to determine if small intestinal bacterial overgrowth contributes to faecal bile acid loss. The study population comprised 40 patients (27 men; median age 18 years) with cystic fibrosis (n = 8) and without (n = 32) liver disease and eight control subjects. Faecal bile acid excretion was significantly higher in cystic fibrosis patients without liver disease compared with control subjects (mean (SEM) 21.5 (2.4) and 7.3 (1.2) micromoles/kg/24 hours respectively; p < 0.01) and patients with liver disease (7.9 (1.3) micromoles/kg/24 hours; p < 0.01). No correlation was found between faecal fat (g fat/24 hours) and faecal bile acid (micromoles 24 hours) excretion. Eight (33%) of cystic fibrosis patients had seven day SeHCAT retention < 10% (normal retention > 20%). SeHCAT retention in cystic fibrosis patients with liver disease was comparable with control subjects (30.0 (SEM) 8.3% v 36.8 (5.9)%; p = NS) while SeHCAT retention in cystic fibrosis patients who did not have liver disease was significantly reduced (19.9 (3.8); p < 0.05). Although evidence of small bowel bacterial overgrowth was present in 40% of patients no relation was found between breath hydrogen excretion, faecal fat, and faecal bile acid loss. The results are consistent with the presence of an abnormality in terminal ideal function in patients with cystic fibrosis who do not have liver disease and that a defect in the ileal absorption of bile acids may be a contributory factor to excessive faecal bile acid loss. Faecal bile acid loss in cystic fibrosis is unrelated to the presence of intraluminal fat or intestinal bacterial overgrowth.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8174969      PMCID: PMC1374370          DOI: 10.1136/gut.34.8.1137

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  21 in total

1.  Aspects of bile acid metabolism in cystic fibrosis.

Authors:  M C Goodchild; G M Murphy; A M Howell; S A Nutter; C M Anderson
Journal:  Arch Dis Child       Date:  1975-10       Impact factor: 3.791

2.  Reduction of bile acid loss in cystic fibrosis by dietary means.

Authors:  C A Smalley; G A Brown; M E Parkes; H Tease; V Brookes; C M Anderson
Journal:  Arch Dis Child       Date:  1978-06       Impact factor: 3.791

Review 3.  Gastrointestinal manifestations of cystic fibrosis: a review.

Authors:  R W Park; R J Grand
Journal:  Gastroenterology       Date:  1981-12       Impact factor: 22.682

4.  Intestinal bile acid malabsorption in cystic fibrosis: a primary mucosal cell defect.

Authors:  J D Fondacaro; J E Heubi; F W Kellogg
Journal:  Pediatr Res       Date:  1982-06       Impact factor: 3.756

5.  Prolonged small-intestinal transit time in cystic fibrosis.

Authors:  A Bali; D E Stableforth; P Asquith
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-08

6.  Se-75-labeled bile acid analogs, new radiopharmaceuticals for investigating the enterohepatic circulation.

Authors:  G S Boyd; M V Merrick; R Monks; I L Thomas
Journal:  J Nucl Med       Date:  1981-08       Impact factor: 10.057

Review 7.  Bile acid metabolism in children with cystic fibrosis.

Authors:  A M Weber; C C Roy
Journal:  Acta Paediatr Scand Suppl       Date:  1985

8.  Bile acid malabsorption in cystic fibrosis; membrane vesicles, a tool for revealing the role of the ileal brush border membrane.

Authors:  F W de Rooij; J W van den Berg; M Sinaasappel; E P Bosman-Jacobs; A C Touw-Blommesteijn
Journal:  Acta Paediatr Scand Suppl       Date:  1985

9.  Bile acid malabsorption in cystic fibrosis with and without pancreatic insufficiency.

Authors:  C Colombo; A Roda; E Roda; L Piceni Sereni; A Brega; R Fugazza; A Giunta
Journal:  J Pediatr Gastroenterol Nutr       Date:  1984-09       Impact factor: 2.839

10.  Evaluation of ileal function using 23-selena-25-homotaurocholate, a-gamma-labeled conjugated bile acid. Initial clinical assessment.

Authors:  H Nyhlin; M V Merrick; M A Eastwood; W G Brydon
Journal:  Gastroenterology       Date:  1983-01       Impact factor: 22.682

View more
  26 in total

1.  Fecal Human β-Defensin 2 in Children with Cystic Fibrosis: Is There a Diminished Intestinal Innate Immune Response?

Authors:  Chee Y Ooi; Tamara Pang; Steven T Leach; Tamarah Katz; Andrew S Day; Adam Jaffe
Journal:  Dig Dis Sci       Date:  2015-08-14       Impact factor: 3.199

2.  Effect of antibiotic treatment on fat absorption in mice with cystic fibrosis.

Authors:  Marjan Wouthuyzen-Bakker; Marcel J C Bijvelds; Hugo R de Jonge; Robert C De Lisle; Johannes G M Burgerhof; Henkjan J Verkade
Journal:  Pediatr Res       Date:  2012-01       Impact factor: 3.756

3.  Prevalence of Fecal Incontinence in Adults with Cystic Fibrosis.

Authors:  Alban Benezech; Nadine Desmazes-Dufeu; Karine Baumstarck; Michel Bouvier; Bérengère Coltey; Martine Reynaud-Gaubert; Véronique Vitton
Journal:  Dig Dis Sci       Date:  2017-10-30       Impact factor: 3.199

4.  Defects in gallbladder emptying and bile Acid homeostasis in mice with cystic fibrosis transmembrane conductance regulator deficiencies.

Authors:  Dominique Debray; Dominique Rainteau; Véronique Barbu; Myriam Rouahi; Haquima El Mourabit; Stéphanie Lerondel; Colette Rey; Lydie Humbert; Dominique Wendum; Charles-Henry Cottart; Paul Dawson; Nicolas Chignard; Chantal Housset
Journal:  Gastroenterology       Date:  2012-02-24       Impact factor: 22.682

5.  Pathophysiological preconditions promoting mixed "black" pigment plus cholesterol gallstones in a DeltaF508 mouse model of cystic fibrosis.

Authors:  Folke Freudenberg; Monika R Leonard; Shou-An Liu; Jonathan N Glickman; Martin C Carey
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-04-29       Impact factor: 4.052

6.  Bioavailability of a novel, water-soluble vitamin E formulation in malabsorbing patients.

Authors:  Konstantinos Papas; John Kalbfleisch; Ricky Mohon
Journal:  Dig Dis Sci       Date:  2007-01-10       Impact factor: 3.199

7.  Impaired mucosal barrier function in the small intestine of the cystic fibrosis mouse.

Authors:  Robert C De Lisle; Racquel Mueller; Megan Boyd
Journal:  J Pediatr Gastroenterol Nutr       Date:  2011-10       Impact factor: 2.839

8.  Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine.

Authors:  Oxana Norkina; Tim G Burnett; Robert C De Lisle
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

9.  Enteric circular muscle dysfunction in the cystic fibrosis mouse small intestine.

Authors:  R C de Lisle; R Sewell; L Meldi
Journal:  Neurogastroenterol Motil       Date:  2009-10-08       Impact factor: 3.598

10.  Pathophysiological basis of liver disease in cystic fibrosis employing a DeltaF508 mouse model.

Authors:  Folke Freudenberg; Annemarie L Broderick; Bian B Yu; Monika R Leonard; Jonathan N Glickman; Martin C Carey
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-04-24       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.